[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605363":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":32,"centralContacts":33,"locations":39,"responsibleParty":159,"collaborators":161,"id":165,"slug":166,"hasResults":167,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":167,"sex":173,"minAge":174,"maxAge":175,"enrollmentInfo":176,"targetDuration":32,"studyType":179,"phases":180,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":42,"whyStopped":32,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":199},{"fullName":5,"class":6},"AAVantgarde Bio Srl","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","EXPERIMENTAL","AAVB-039 dose level 1 (low dose)",[13],"Biological: AAVB-039",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2","AAVB-039 dose level 2 (mid dose)",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Cohort 3","AAVB-039 dose level 3 (high dose)",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Cohorts 4-5","AAVB-039 dose level 1, 2 or 3",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"BIOLOGICAL","AAVB-039","Single subretinal administration",[9,15,19,23],null,[34],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},"AAVantgarde Clinical Operations Lead","CONTACT","+448000465680","clinicaltrials@aavantgarde.com",[40,61,80,97,110,125,141,153],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Associated Retina Consultants","RECRUITING","Phoenix","Arizona","85020","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-112.07404,33.44838,{"lat":52,"lon":51},[55,58],{"name":56,"role":36,"phone":32,"phoneExt":32,"email":57},"Study Team","hello@doctrials.com",{"name":59,"role":60,"phone":32,"phoneExt":32,"email":32},"Benjamin Bakall","PRINCIPAL_INVESTIGATOR",{"facility":62,"status":42,"city":63,"state":64,"zip":65,"country":46,"countryCode":47,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Retina Vitreous Associates Medical Group","Los Angeles","California","90211",{"type":49,"coordinates":67},[68,69],-118.24368,34.05223,{"lat":69,"lon":68},[72,75,78],{"name":73,"role":36,"phone":32,"phoneExt":32,"email":74},"Kristina Passoian, Trials Director","Kpassoian@laretina.com",{"name":76,"role":36,"phone":32,"phoneExt":32,"email":77},"Study Referrals","Studyreferrals@laretina.com",{"name":79,"role":60,"phone":32,"phoneExt":32,"email":32},"David Liao",{"facility":81,"status":42,"city":82,"state":83,"zip":84,"country":46,"countryCode":47,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Mayo Clinic","Rochester","Minnesota","55905",{"type":49,"coordinates":86},[87,88],-92.4699,44.02163,{"lat":88,"lon":87},[91,95],{"name":92,"role":36,"phone":93,"phoneExt":32,"email":94},"Suzy Wernimont","507-538-8119","Wernimont.Suzanne@mayo.edu",{"name":96,"role":60,"phone":32,"phoneExt":32,"email":32},"Brittni Scruggs",{"facility":98,"status":42,"city":99,"state":100,"zip":101,"country":46,"countryCode":47,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"Retina Consultants of Texas","Bellaire","Texas","77401",{"type":49,"coordinates":103},[104,105],-95.45883,29.70579,{"lat":105,"lon":104},[108],{"name":109,"role":60,"phone":32,"phoneExt":32,"email":32},"Kenneth Fan",{"facility":111,"status":42,"city":112,"state":100,"zip":113,"country":46,"countryCode":47,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"Retina Foundation of the Southwest","Dallas","75231",{"type":49,"coordinates":115},[116,117],-96.80667,32.78306,{"lat":117,"lon":116},[120,123],{"name":121,"role":36,"phone":32,"phoneExt":32,"email":122},"Senior Clinical Research Coordinator","jclark@retinafoundation.org",{"name":124,"role":60,"phone":32,"phoneExt":32,"email":32},"Karl Csaky",{"facility":126,"status":42,"city":127,"state":128,"zip":129,"country":46,"countryCode":47,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"University of Utah","Salt Lake City","Utah","84112",{"type":49,"coordinates":131},[132,133],-111.89105,40.76078,{"lat":133,"lon":132},[136,139],{"name":137,"role":36,"phone":32,"phoneExt":32,"email":138},"Kimberley Wegner Lead Coordinator","Kimberley.wegner@hsc.utah.edu",{"name":140,"role":60,"phone":32,"phoneExt":32,"email":32},"Paul Bernstein",{"facility":142,"status":42,"city":143,"state":144,"zip":145,"country":146,"countryCode":147,"cosmosGeoPoint":148,"geoPoint":152,"contacts":32},"Moorfields Eye Hospital NHS Foundation Trust","London","England","EC1V 2PD","United Kingdom","UK",{"type":49,"coordinates":149},[150,151],-0.12574,51.50853,{"lat":151,"lon":150},{"facility":154,"status":42,"city":143,"state":144,"zip":155,"country":146,"countryCode":147,"cosmosGeoPoint":156,"geoPoint":158,"contacts":32},"The Retina Clinic","W1G 9AX",{"type":49,"coordinates":157},[150,151],{"lat":151,"lon":150},{"type":160,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR",[162],{"name":163,"class":164},"AAVantgarde Bio UK Ltd","UNKNOWN","100605363","phase-1-a-study-of-aavb-039-in-participants-with-stargardt-disease-stgd1-100605363",false,"NCT07161544","A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)","An Open-label, Multicenter, Two Part, Ascending Dose Followed by a Controlled Trial to Assess the Safety and Efficacy of a Subretinal Administration of AAVB-039 in Participants With Stargardt Disease (STGD1) (CELESTE)","CELESTE","Inclusion Criteria:\n\n* Molecular diagnosis of Stargardt disease due to ABCA4 mutation\n* Willingness to adhere to protocol per informed consent\n\nExclusion Criteria:\n\n* Unwillingness to meet the requirements of the study\n* Participation in a clinical study with another Investigation Medicinal Product\n* Previous participation in another gene or cell therapy trial\n* Any condition that would preclude subretinal surgery\n* Complicating ocular and\u002For systemic diseases","ALL","8 Years","55 Years",{"count":177,"type":178},75,"ESTIMATED","INTERVENTIONAL",[181,182],"PHASE1","PHASE2","The purpose of the 039-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-039 in participants with Stargardt disease secondary to a biallelic mutation of the ABCA4 gene. The study will also assess initial efficacy following AAVB-039 administration.",[185],"Stargardt Disease",[185,187,188,189],"Biallelic Mutation","Gene Mutation","ABCA4","2026-06-19",{"date":192,"type":193},"2026-06-23","ACTUAL",{"date":195,"type":193},"2025-09-29",{"date":197,"type":178},"2032-07",{"name":5,"class":6},8]